Lung Cancer News and Research

Latest Lung Cancer News and Research

Retreating with gefitinib may benefit non-small cell lung cancer patients

Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.

13 Jan 2010

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

At least three tumor microRNAs appear to predict when first-line chemotherapy will prove ineffective in some patients with small cell lung cancer, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held Jan. 11-14, 2010.

13 Jan 2010

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.

13 Jan 2010

Green tea could modulate smoke-induced lung cancer

Drinking green tea could modulate the effect of smoking on lung cancer. Results of this hospital-based, randomized study conducted in Taiwan were presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held here from Jan. 11-14, 2010.

13 Jan 2010

Blood test may be effective for diagnosing lung cancer

Of the nearly 150,000 abnormal chest X-rays performed each year in the United States, 25 percent of patients will display only benign lung pathologies on further surgical examination.

13 Jan 2010

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).

13 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.

12 Jan 2010

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway’) to those treated with non-evidence-based guidelines (also known as ‘off pathway’), was published in the peer-reviewed Journal of Oncology Practice.

12 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

Winter months presents a good opportunity to test our homes for radon

Keeping our homes more tightly closed during the winter months allows indoor air pollutants to build up in higher concentrations. It presents a good opportunity to test our homes for radon, a colourless, odourless gas that is produced from the natural breakdown of uranium in rocks and soil.

9 Jan 2010

Research determines and validates the efficacy of T category in IASLC's Staging Manual

Research released in the January 2010 issue of the Journal of Thoracic Oncology sought to determine and validate the efficacy of the recent reclassification of the T category in the IASLC's Staging Manual in Thoracic Oncology.

9 Jan 2010

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.

8 Jan 2010

MUHC unveils new Lung Cancer Navigation Program

A diagnosis of lung cancer can come as a hard blow. The disease has one of the highest mortality rates of all cancers and the sheer complexity of therapy - often involving radiation, chemotherapy and surgery - can leave patients feeling confused and isolated. To help these patients navigate through the complicated treatment process and medical appointments, the MUHC has unveiled its new Lung Cancer Navigation Program (LCNP).

8 Jan 2010

Final health care reform legislation requires comprehensive coverage of smoking cessation treatment

As Congress negotiates a final health care reform bill, lawmakers should seize this unprecedented opportunity to invest in proven measures that prevent costly diseases from occurring in the first place, which will improve health and reduce health care costs. These include measures to prevent and reduce tobacco use, which remains the leading cause of preventable death in the United States, killing more than 400,000 people and costing the nation $96 billion in health care expenditures annually.

8 Jan 2010

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

Promising results from Phase II clinical trials and important biological advances in diagnosis and prognosis will be presented here, at the conference on Molecular Origins of Lung Cancer from Jan. 11-14, 2010. This conference is jointly sponsored by the AACR and the International Association for the Study of Lung Cancer.

7 Jan 2010

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, and Genetic Technologies Ltd. (ASX: GTG; NASDAQ: GENE), the leading private genetic testing laboratory in Australia, today announced an exclusive distribution and services agreement.

7 Jan 2010

New study reveals high-silica coal causes lung cancer

The volcanic eruptions thought responsible for Earth's largest mass extinction - which killed more than 70 percent of plants and animals 250 million years ago - is still taking lives today. That's the conclusion of a new study showing, for the first time, that the high silica content of coal in one region of China may be interacting with volatile substances in the coal to cause unusually high rates of lung cancer.

6 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

'Make Today the Day' public awareness campaign to quit smoking launched

At a time when many smokers consider quitting for the New Year, today is a timely launch of a partnership that joins together mutual public health interests sought by the American Lung Association in California, Healthy San Francisco and the city's Public Health Office in a citywide public awareness campaign aimed to help smokers achieve that goal.

6 Jan 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Retreating with gefitinib may benefit non-small cell lung cancer patients

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Green tea could modulate smoke-induced lung cancer

Blood test may be effective for diagnosing lung cancer

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Winter months presents a good opportunity to test our homes for radon

Research determines and validates the efficacy of T category in IASLC's Staging Manual

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

MUHC unveils new Lung Cancer Navigation Program

Final health care reform legislation requires comprehensive coverage of smoking cessation treatment

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

New study reveals high-silica coal causes lung cancer

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

'Make Today the Day' public awareness campaign to quit smoking launched

The ultimate guide to lung research tools and protocols eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in